Skip to content

Posttraumatic Stress Disorder (PTSD)

BASICS

  • Definition: Psychiatric disorder after experiencing or witnessing traumatic events (death, sexual violence, serious injury, or threat thereof).
  • Core Symptom Clusters: (≥1 month for diagnosis)
  • Intrusion: Flashbacks, nightmares, distressing recollections
  • Avoidance/Numbing: Avoid trauma reminders; emotional detachment
  • Negative Alterations in Mood/Cognition: Amnesia, negative beliefs, detachment, inability to experience positive emotions
  • Increased Arousal/Reactivity: Sleep disturbance, irritability, hypervigilance, concentration issues, self-destructive behavior

EPIDEMIOLOGY

  • Incidence: ~7.7 million U.S. adults/year (3.5%)
  • Lifetime prevalence: 6.8%
  • Highest risk traumas: Unexpected death of loved one, rape, sexual assault
  • 16% of trauma-exposed children/adolescents develop PTSD

ETIOLOGY & PATHOPHYSIOLOGY

  • Biological: Catecholamine hypersensitivity, opioid pathway overactivity, amygdala/hippocampus dysfunction, serotonergic & glutamatergic dysregulation
  • Learning Theory: Trauma cues → conditioned fear response (“fight-or-flight”)
  • Cognitive/Psychodynamic: Persistent trauma memories overwhelm defenses, drive repeated recall

RISK FACTORS

  • Pre-existing: Female sex, young age, psychiatric history, low SES
  • Peritrauma: Severe trauma, intense emotional response, threat perception
  • Posttrauma: Injury severity, complications, poor social support, persistent dissociation, further trauma exposure

GENERAL PREVENTION

  • Trauma-focused CBT and prolonged exposure (delivered within weeks after trauma) best supported for prevention in distressed individuals.

COMMONLY ASSOCIATED CONDITIONS

  • Adults: Depression, substance abuse, panic/social phobias, OCD, dementia, smoking (esp. after assault)
  • Pediatrics: Oppositional defiant disorder, separation anxiety

DIAGNOSIS

DSM-5 Criteria

  • A: Trauma exposure (direct, witnessed, learned about close other, or repeated exposure to details)
  • B: Intrusion (≥1 symptom)
  • C: Avoidance (≥1)
  • D: Negative mood/cognition (≥2)
  • E: Hyperarousal (≥2)
  • F: Duration >1 month
  • G: Clinically significant distress/functional impairment
  • H: Not due to substance or medical illness

Pediatric Note:

  • Separation fears, regressive behaviors, somatic complaints, school avoidance, nightmares, irritability

HISTORY & EXAM

  • Symptoms: Intrusion, avoidance, mood/cognition changes, hyperarousal (>1 month)
  • Exam: May see agitation, poor hygiene, altered affect, memory/concentration deficits, poor impulse control, somatic injury from trauma
  • Pediatrics: Heart rate elevation after trauma may predict PTSD

DIFFERENTIAL DIAGNOSIS

  • GAD, adjustment disorder, OCD, schizophrenia, depression/mood disorder, substance abuse, dissociative/personality disorders, malingering

DIAGNOSTIC TOOLS

  • Primary Care PTSD Screen (PC-PTSD-5)
  • Trauma Screening Questionnaire (TSQ)

TREATMENT

General Principles

  • Best outcomes with psychotherapy + pharmacotherapy soon after trauma.
  • CBT (trauma-focused/exposure): Gold standard; includes EMDR.
  • Telemedicine/collaborative care: Effective in multiple settings.

Medication

First-Line (SSRIs)

  • Sertraline: 50–200 mg daily (FDA-approved)
  • Paroxetine: Start 10 mg, titrate up (FDA-approved)
  • Fluoxetine: 20–80 mg/day

Sleep/Nightmares

  • Trazodone 50–300 mg QHS
  • Mirtazapine 7.5–30 mg QHS
  • Amitriptyline 25–100 mg QHS
  • Prazosin 2–15 mg QHS for nightmares
  • Clonidine 0.1–0.2 mg QHS

Second-Line/Augmentation

  • SNRIs: Venlafaxine, duloxetine, desvenlafaxine
  • Mirtazapine: 15–45 mg/day
  • Antipsychotics: Aripiprazole, risperidone, olanzapine, quetiapine (for intrusive thoughts, hyperarousal)
  • Alpha-agonists: Clonidine, guanfacine (hyperarousal)
  • Mood stabilizers: Valproic acid, carbamazepine, topiramate (impulsivity)
  • Anxiety: Hydroxyzine or (rarely) risperidone PRN (avoid benzodiazepines)

Children:

  • Little evidence for medication; focus on therapy.

ONGOING CARE

  • Long-term therapy: May be needed, especially in complex PTSD/childhood sexual abuse.
  • Monitor for retraumatization, comorbidities.
  • Parent PTSD is a strong predictor of pediatric PTSD.
  • Education: National Center for PTSD—https://www.ptsd.va.gov

PROGNOSIS

  • 50% remit in 3 months; others have persistent/life-long impairment.
  • Better outcomes: Early treatment, good support, avoidance of retraumatization, absence of comorbidities

COMPLICATIONS

  • Increased risk for panic/social/OCD, depression, suicide, homicide, substance abuse
  • Sexual assault survivors are at especially high risk for severe sequelae

ICD-10 CODES

  • F43.10 Post-traumatic stress disorder, unspecified
  • F43.11 PTSD, acute
  • F43.12 PTSD, chronic

CLINICAL PEARLS

  • Combined psychotherapy and pharmacotherapy is most effective.
  • Exposure-based therapies (CBT, EMDR) have highest evidence.
  • SSRIs are first-line medications.
  • Avoid benzodiazepines due to poor efficacy and risk of misuse.
  • Pediatric PTSD is common—parental stress must be addressed.